Development of Organometallic S6K1 Inhibitors

作者：Qin Jie; Rajaratnam Rajathees; Feng Li; Salami Jemilat; Barber Rotenberg Julie S; Domsic John; Reyes Uribe Patricia; Liu Haiying; Dang Weiwei; Berger Shelley L; Villanueva Jessie; Meggers Eric^*; Marmorstein Ronen

来源：Journal of Medicinal Chemistry, 2015, 58(1): 305-314.

DOI：10.1021/jm5011868

Aberrant activation of S6 kinase 1 (S6K1) is found in many diseases, including diabetes, aging, and cancer. We developed ATP competitive organometallic kinase inhibitors, EM5 and FL772, which are inspired by the structure of the pan-kinase inhibitor staurosporine, to specifically inhibit S6K1 using a strategy previously used to target other kinases. Biochemical data demonstrate that EM5 and FL772 inhibit the kinase with IC50 value in the low nanomolar range at 100 mu M ATP and that the more potent FL772 compound has a greater than 100-fold specificity over S6K2. The crystal structures of S6K1 bound to staurosporine, EM5, and FL772 reveal that the EM5 and FL772 inhibitors bind in the ATP binding pocket and make S6K1-specific contacts, resulting in changes to the p-loop, alpha C helix, and aD helix when compared to the staurosporine-bound structure. Cellular data reveal that FL772 is able to inhibit S6K phosphorylation in yeast cells. Together, these studies demonstrate that potent, selective, and cell permeable S6K1 inhibitors can be prepared and provide a scaffold for future development of S6K inhibitors with possible therapeutic applications.

• 出版日期2015-1-8